The global vutrisiran market garnered a market value of USD 600 Million in 2022 and is expected to accumulate a market value of USD 2,087 Million by registering a CAGR of 12% in the forecast period 2023 to 2033. The expansion of the market can be credited to Vutrisiran, which provides optimism and a fresh therapeutic choice for individuals who have hereditary transthyretin-mediated amyloidosis (hATTR). The market for vutrisiran registered a CAGR of 5.1% in the historical period 2018 to 2022
Vutrisiran is a medication used to treat hereditary transthyretin-mediated amyloidosis (hATTR), a rare and progressive genetic disease that affects multiple organs and tissues, including the nerves, heart, and kidneys. The drug works by using RNA interference (RNAi) technology to silence the production of the protein responsible for the abnormal accumulation of amyloid fibrils in the body.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 671.96 Million |
| Anticipated Forecast Value (2033) | USD 2,087 Million |
| Projected Growth Rate (2023 to 2033) | 12% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Vutrisiran reflected a value CAGR of 5.1% during the historical period, 2018 to 2022.
Vutrisiran received approval from the United States Food and Drug Administration (FDA) in September 2021 and approval from the European Medicines Agency (EMA) in November 2021. It is currently available in the United States, Europe, and other regions.
Based on the positive results of clinical trials and the approval by regulatory agencies, it is possible that the market for Vutrisiran may grow in the coming years. Thus, the market for vutrisiran is expected to register a CAGR of 12% in the forecast period 2023 to 2033.
High unmet medical need along with growing prevalence of hATTR driving market growth
Hereditary transthyretin-mediated amyloidosis (hATTR) is a rare and progressive genetic disease that currently has limited treatment options. Vutrisiran provides a new treatment option that targets the root cause of the disease and has shown promising results in clinical trials. As a result, there is a high unmet medical need for effective treatments for hATTR, which could drive demand for Vutrisiran.
The prevalence of hATTR is increasing due to improved diagnosis and increased awareness of the disease. This trend is expected to continue in the coming years, which could result in a larger patient pool for Vutrisiran. The recent regulatory approvals of Vutrisiran by the FDA and the EMA have expanded the availability of the medication to more regions, which could drive demand for the drug.
The availability of favorable reimbursement policies by insurance companies and government healthcare systems can make Vutrisiran more accessible to patients and drive market growth. Alnylam Pharmaceuticals, the company that developed Vutrisiran, has a strong pipeline of other RNAi-based therapies in development for a range of diseases. The success of Vutrisiran could drive investor confidence in the company and increase funding for its other pipeline drugs, which could in turn drive the growth of the Vutrisiran market.
Principal Consultant
Development of alternative medication and expensive nature of vutrisiran derailing market growth
Although there are limited treatment options for hATTR, there are other drugs in development for the disease, such as Pfizer's tafamidis. If these drugs prove to be effective and gain regulatory approval, they could compete with Vutrisiran and impact its market growth.
Vutrisiran is a high-cost medication, which could pose challenges for patient access and reimbursement. Insurers and government healthcare systems may be hesitant to cover the cost of the drug, which could limit its market growth. As with any new drug, there may be concerns about the long-term safety of Vutrisiran. This could impact patient and physician confidence in the medication and limit its market growth.
Despite growing awareness of hATTR, the disease is still relatively unknown and underdiagnosed. This could limit the size of the patient pool for Vutrisiran and impact its market growth. The manufacturing of RNAi-based therapies like Vutrisiran can be complex and expensive. If Alnylam Pharmaceuticals is not able to scale up its manufacturing capacity to meet demand, it could limit the availability of the drug and impact its market growth.
Favorable reimbursement policies propelling market growth in North America
The approval of Vutrisiran has opened up the North American market, including the United States and Canada, for the treatment of hATTR. The market for Vutrisiran in North America is expected to grow as the drug becomes more widely available and awareness of hATTR increases among healthcare professionals and patients.
Factors such as the high prevalence of hATTR in North America, the availability of favorable reimbursement policies, and the strong pipeline of RNAi-based therapies being developed by Alnylam Pharmaceuticals, the company that developed Vutrisiran, could contribute to the growth of the Vutrisiran market in North America. Thus, North America is expected to possess a 45% market share for the vutrisiran market in 2023.
Research and development of medication by key players favoring market growth in Europe
In July 2021, Vutrisiran received regulatory approval from the European Medicines Agency (EMA) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) in adults with polyneuropathy. This has opened up the European market for Vutrisiran and is expected to drive the growth of the market.
Alnylam Pharmaceuticals, the company that developed Vutrisiran, has a strong pipeline of other RNAi-based therapies in development for a range of diseases. The success of Vutrisiran could drive investor confidence in the company and increase funding for its other pipeline drugs, which could in turn drive the growth of the vutrisiran market in Europe. Thus, Europe is expected to possess 41% market share for vutrisiran market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Availability of resources increasing dependency on hospital pharmacies for vutrisian
Hospital pharmacies are specialized in managing and dispensing drugs used in the hospital setting, including high-cost medications like Vutrisiran. This specialization ensures that the hospital pharmacy staff has the expertise and resources to properly handle and dispense Vutrisiran.
Vutrisiran is a high-cost medication that requires careful monitoring of patients to ensure its safety and effectiveness. Hospital pharmacies can provide this level of monitoring and support, as they have access to patient medical records and can work closely with healthcare providers to monitor patients' responses to Vutrisiran.
Vutrisiran is administered via intravenous infusion, which requires specialized equipment and trained personnel. Hospital pharmacies have access to these resources and can ensure that Vutrisiran is properly administered to patients. Hospital pharmacies have access to resources such as 24/7 staffing, emergency equipment, and clinical expertise that can be crucial in the management of patients receiving Vutrisiran.
Hospital pharmacies can work closely with other healthcare providers, including physicians, nurses, and other support staff, to ensure that patients receiving Vutrisiran receive the best possible care. Thus, hospital pharmacies are expected to possess 46% market share for vutrisiran market in 2023.
Key players in the vutrisiran market are Alnylam Pharmaceuticals, Inc., Orphalan, AstraZeneca, Vivet Therapeutics, Pfizer, Ultragenyx Pharmaceutical, Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Merck & Co., Inc., Teva Pharmaceuticals
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 671.96 million |
| Market Value in 2033 | USD 2,087 million |
| Growth Rate | CAGR of 12% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Drug Class, Route of Administration, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, United kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Austria, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Alnylam Pharmaceuticals, Inc.; Orphalan; AstraZeneca; Vivet Therapeutics; Pfizer Inc.; Ultragenyx Pharmaceutical; Valeant Pharmaceuticals International, Inc.; Noblepharma Co., Ltd.; Merck & Co., Inc.; Teva Pharmaceuticals |
| Customization | Available Upon Request |
The market is valued at USD 671.9 million in 2023.
The market’s CAGR from 2023 to 2033 will be 12.0%.
Orphalan, AstraZeneca, and Vivet Therapeutics are key market players.
Hospital pharmacies segment is likely to remain preferred through 2033.
The market will reach USD 2.0 billion by 2033.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Antisense Oligonucleotides 5.2. Nucleic Acids 5.3. Nucleotide 5.4. Nucleosides 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Injectable 6.2. Parenteral 6.3. Subcutaneous 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Hospital Pharmacy 7.2. Online Pharmacy 7.3. Retail Pharmacy 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. Middle East & Africa 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Middle East & Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Alnylam Pharmaceuticals, Inc. 18.2. Orphalan 18.3. AstraZeneca 18.4. Vivet Therapeutics 18.5. Pfizer 18.6. Ultragenyx Pharmaceutical 18.7. Valeant Pharmaceuticals International, Inc. 18.8. Noblepharma Co., Ltd. 18.9. Merck & Co., Inc. 18.10. Teva Pharmaceuticals 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Vutrisiran Market
